Current status of traditional Chinese medicine for the treatment of COVID-19 in China.
Chin Med. 2021 Jul 27; 16(1):63.CM

Abstract

An ongoing outbreak of severe respiratory illness and pneumonia caused by the severe acute respiratory coronavirus 2 (SARS-CoV-2) commenced in December 2019, and the disease was named as coronavirus disease 2019 (COVID-19). Soon after, scientists identified the characteristics of SARS-CoV-2, including its genome sequence and protein structure. The clinical manifestations of COVID-19 have now been established; and nucleic acid amplification is used for the direct determination of the virus, whereas immunoassays can determine the antibodies against SARS-CoV-2. Clinical trials of several antiviral drugs are ongoing. However, there is still no specific drugs to treat COVID-19. Traditional Chinese medicine (TCM) was used in the treatment of COVID-19 during the early stages of the outbreak in China. Some ancient TCM prescriptions, which were efficacious in the treatment of severe acute respiratory syndrome (SARS) in 2002-03 and the influenza pandemic (H1N1) of 2009, have been improved by experienced TCM practitioners for the treatment of COVID-19 based on their clinical symptoms. These developed new prescriptions include Lianhua Qingwen capsules/granules, Jinhua Qinggan granules and XueBiJing injection, among others. In this review, we have summarized the presenting features of SARS-CoV-2, the clinical characteristics of COVID-19, and the progress in the treatment of COVID-19 using TCMs.

Links

PMC Free PDF

Authors+Show Affiliations

Chu L

Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1095 Jie Fang Avenue, Wuhan, 430030, Hubei, China. liangchu@tjh.tjmu.edu.cn.

Huang F

Department of Pathology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China.

Zhang M

College of Life and Medicine Sciences, Zhejiang Sci-Tech University, No. 928, 2nd Street, Xiasha Higher Education Park, Hangzhou, 310018, Zhejiang, China.

Huang B

College of Life and Medicine Sciences, Zhejiang Sci-Tech University, No. 928, 2nd Street, Xiasha Higher Education Park, Hangzhou, 310018, Zhejiang, China.

Wang Y

College of Life and Medicine Sciences, Zhejiang Sci-Tech University, No. 928, 2nd Street, Xiasha Higher Education Park, Hangzhou, 310018, Zhejiang, China. wangyigang43@163.com.

Pub Type(s)

Journal Article

Review

Language

eng

PubMed ID

34315521

Citation

Chu, Liang, et al. "Current Status of Traditional Chinese Medicine for the Treatment of COVID-19 in China." Chinese Medicine, vol. 16, no. 1, 2021, p. 63.

Chu L, Huang F, Zhang M, et al. Current status of traditional Chinese medicine for the treatment of COVID-19 in China. Chin Med. 2021;16(1):63.

Chu, L., Huang, F., Zhang, M., Huang, B., & Wang, Y. (2021). Current status of traditional Chinese medicine for the treatment of COVID-19 in China. Chinese Medicine, 16(1), 63. https://doi.org/10.1186/s13020-021-00461-y

Chu L, et al. Current Status of Traditional Chinese Medicine for the Treatment of COVID-19 in China. Chin Med. 2021 Jul 27;16(1):63. PubMed PMID: 34315521.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - Current status of traditional Chinese medicine for the treatment of COVID-19 in China. AU - Chu,Liang, AU - Huang,Fang, AU - Zhang,Mengdan, AU - Huang,Biao, AU - Wang,Yigang, Y1 - 2021/07/27/ PY - 2021/04/18/received PY - 2021/06/26/accepted PY - 2021/7/28/entrez PY - 2021/7/29/pubmed PY - 2021/7/29/medline KW - COVID-19 KW - Clinical treatment KW - SARS-CoV-2 KW - Traditional Chinese medicine SP - 63 EP - 63 JF - Chinese medicine JO - Chin Med VL - 16 IS - 1 N2 - An ongoing outbreak of severe respiratory illness and pneumonia caused by the severe acute respiratory coronavirus 2 (SARS-CoV-2) commenced in December 2019, and the disease was named as coronavirus disease 2019 (COVID-19). Soon after, scientists identified the characteristics of SARS-CoV-2, including its genome sequence and protein structure. The clinical manifestations of COVID-19 have now been established; and nucleic acid amplification is used for the direct determination of the virus, whereas immunoassays can determine the antibodies against SARS-CoV-2. Clinical trials of several antiviral drugs are ongoing. However, there is still no specific drugs to treat COVID-19. Traditional Chinese medicine (TCM) was used in the treatment of COVID-19 during the early stages of the outbreak in China. Some ancient TCM prescriptions, which were efficacious in the treatment of severe acute respiratory syndrome (SARS) in 2002-03 and the influenza pandemic (H1N1) of 2009, have been improved by experienced TCM practitioners for the treatment of COVID-19 based on their clinical symptoms. These developed new prescriptions include Lianhua Qingwen capsules/granules, Jinhua Qinggan granules and XueBiJing injection, among others. In this review, we have summarized the presenting features of SARS-CoV-2, the clinical characteristics of COVID-19, and the progress in the treatment of COVID-19 using TCMs. SN - 1749-8546 UR - https://www.unboundmedicine.com/medline/citation/34315521/Current_status_of_traditional_Chinese_medicine_for_the_treatment_of_COVID_19_in_China_ DB - PRIME DP - Unbound Medicine ER -

Tags

Current status of traditional Chinese medicine for the treatment of COVID-19 in China.Chin Med. 2021 Jul 27; 16(1):63.CM